Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma

Genetics and Molecular Research

Volumn 8, Issue 4, 2009, Pages 1257-1263

  Anselmo, N P ^a,d   Rey, J A ^b   Almeida, L O ^a   Custodio A C ^a   Almeida, J R W ^c   Clara, C A ^c   Santos, M J ^c   Casartelli, C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c BARRETOS CANCER HOSPITAL   (Brazil)

^d FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

Astrocytoma; TP53 gene; TP73 gene

Indexed keywords

PROTEIN P53; PROTEIN P73;

ADULT; ARTICLE; CASE REPORT; DNA BINDING; DNA POLYMORPHISM; EXON; GENE DELETION; GENE MUTATION; GENE SEQUENCE; GLIOBLASTOMA; HUMAN; INTRON; MALE; POLYMERASE CHAIN REACTION;

ADULT; ASTROCYTOMA; BASE SEQUENCE; BRAIN NEOPLASMS; DNA PRIMERS; DNA-BINDING PROTEINS; HUMANS; MALE; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 73449134137     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol8-4gmr631     Document Type: Article

References (35)

1. Alonso ME, Bello MJ, Gonzalez-Gomez P, Lomas J, et al. (2001a). Mutation analysis of the p73 gene in nonastrocytic brain tumours. Br. J. Cancer 85: 204-208.
2. Alonso ME, Bello MJ, Lomas J, Gonzalez-Gomez P, et al. (2001b). Absence of mutation of the p73 gene in astrocytic neoplasms. Int. J. Oncol. 19: 609-612.
3. Arrowsmith CH (1999). Structure and function in the p53 family. Cell Death Differ. 6: 1169-1173.
4. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, et al. (1997). Further characterisation of the p53 responsive element - identification of new candidate genes for trans-activation by p53. Oncogene 14: 85-94.
5. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, et al. (2005). p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19: 2122-2137.
6. D'Erchia AM, Tullo A, Pesole G, Saccone C, et al. (2003). p53 gene family: structural, functional and evolutionary features. Curr. Genomics 4: 13-26.
7. De Laurenzi VD, Catani MV, Terrinoni A, Corazzari M, et al. (1999). Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants epsilon and zeta. Cell Death Differ. 6: 389-390.
8. Farmer G, Bargonetti J, Zhu H, Friedman P, et al. (1992). Wild-type p53 activates transcription in vitro. Nature 358: 83-86.
9. Finlay CA, Hinds PW and Levine AJ (1989). The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093.
10. Ge H, Wang YM, Cao YY, Chen ZF, et al. (2007). The p73 polymorphisms are not associated with susceptibility to esophageal squamous cell carcinoma in a high incidence region of China. Dis. Esophagus 20: 290-296.
11. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, et al. (1997). Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J. Natl. Cancer Inst. 89: 1036-1044.
12. Haas-Kogan DA, Yount G, Haas M, Levi D, et al. (1996). p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 36: 95-103.
13. Holland JF and Frei MDE III (1982). Cancer Medicine. 2nd edn. Lea and Febiger, Philadelphia.
14. Kleihues P (1998). Subsets of glioblastoma: clinical and histological vs. genetic typing. Brain Pathol. 8: 667-668.
15. Kleihues P and Cavenee WK (2000). Pathology and Genetics. Tumors of the Nervous System. World Health Organization Classification of Tumours. IARC Press, Lyon.
16. Ko LJ and Prives C (1996). p53: puzzle and paradigm. Genes Dev. 10: 1054-1072.
17. Levrero M, De Laurenzi V, Costanzo A, Gong J, et al. (1999). Structure, function and regulation of p63 and p73. Cell Death Differ. 6: 1146-1153.
18. Levrero M, De Laurenzi V, Costanzo A, Gong J, et al. (2000). The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. 113 (Pt 10): 1661-1670.
19. Melino G, Lu X, Gasco M, Crook T, et al. (2003). Functional regulation of p73 and p63: development and cancer. Trends Biochem. Sci. 28: 663-670.
20. Michael D and Prados MD (2000). Neoplasms of the Central Nervous System - Molecular Genetics. In: Cancer Medicine. 5th edn (Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, et al., eds.). BC Decker Inc., Hamilton.
21. Milner J and Medcalf EA (1991). Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65: 765-774.
22. Moll UM and Slade N (2004). p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2: 371-386.
23. Nozaki M, Tada M, Kobayashi H, Zhang CL, et al. (1999). Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-Oncol. 1: 124-137.
24. Ohgaki H and Kleihues P (2007). Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 170: 1445-1453.
25. Petitjean A, Mathe E, Kato S, Ishioka C, et al. (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28: 622-629.
26. Reifenberger J, Ring GU, Gies U, Cobbers L, et al. (1996). Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol. 55: 822-831.
27. Rey JA, Bello MJ, Jimenez-Lara AM, Vaquero J, et al. (1992). Loss of heterozygosity for distal markers on 22q in human gliomas. Int. J. Cancer 51: 703-706.
28. Sbisá E, Catalano D, Grillo G, Licciulli F, et al. (2007). p53FamTaG: a database resource of human p53, p63 and p73 direct target genes combining in silico prediction and microarray data. BMC Bioinformatics 8 (Suppl 1): S20.
29. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, et al. (1992). Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 355: 846-847.
30. Ueda Y, Hijikata M, Takagi S, Chiba T, et al. (1999). New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18: 4993-4998.
31. von Deimling A, Bender B, Louis DN and Wiestler OD (1993). A rapid and non-radioactive PCR based assay for the detection of allelic loss in human gliomas. Neuropathol. Appl. Neurobiol. 19: 524-529.
32. Vogelstein B, Lane D and Levine AJ (2000). Surfing the p53 network. Nature 408: 307-310.
33. Vousden KH and Lu X (2002). Live or let die: the cell's response to p53. Nat. Rev. Cancer 2: 594-604.
34. Watanabe K, Sato K, Biernat W, Tachibana O, et al. (1997). Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 3: 523-530.
35. Zhu J, Jiang J, Zhou W and Chen X (1998). The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58: 5061-5065.